To ensure the accuracy of our patient satisfaction scores, we require that providers who see patients receive
a minimum number of completed patient-submitted surveys before their reviews are listed on their profiles.
Star ratings on this site are collected on a rolling basis from the previous 12 months.
Additionally, some of the physicians listed on our site do not see patients directly, and therefore, do not receive
evaluation and ratings from patients.
Associate Director, Community Outreach and Engagement (COE)
As an expert in community-engaged research, much of my work involves studies on cancer disparities, primarily prostate cancer, and how certain risk factors influence cancer occurrence, progression, and treatment outcomes. Among some of these risk factors are race/ethnicity, neighborhood characteristics, genetic polymorphisms, inflammation biomarkers, obesity, and socioeconomic status. To address this, my team and I focus our research goals on identifying possible modes for cancer prevention in high-risk populations and providing new understanding about how contextual factors influence disease outcomes.
Charnita Zeigler-Johnson works with community partners as well as cancer center leadership and clinical chairs to address the needs of the communities that Fox Chase serves. She also integrates community-engaged research across scientific programs at Fox Chase and Temple Health.
As Associate Director of Community Outreach and Engagement (COE), Charnita Zeigler-Johnson oversees the activities of COE as the academic lead for this team. As an advocate for this work, she:
champions efforts to provide community cancer education and mobile screening services;
prioritizes education outreach focusing on cancers with the highest incidence and mortality in the Fox Chase and Temple Health catchment areas, including breast, lung, prostate, colon, liver, and cervical cancers;
supports community-based lifestyle interventions targeting diet, nutrition, physical activity, tobacco control, and other behaviors that lower cancer risk and potentially improve cancer survival;
conducts local community education, patient navigation, and delivery of research interventions;
and serves as a liaison between scientists and community partners.
Zeigler-Johnson joined Fox Chase from Thomas Jefferson University, where she was an associate professor in the Division of Population Science, Department of Medical Oncology, and an associate professor in the College of Population Health. She also served as an adjunct scholar in the Center for Clinical Epidemiology and Biostatistics at the University of Pennsylvania...Expand
A well-funded investigator with more than 50 peer-reviewed publications to her credit, Zeigler-Johnson’s research interests focus on the relationship between community history and prostate cancer disparities, as well as increasing lung cancer screening access and adherence in vulnerable populations. She has lectured locally, nationally, and internationally, and has served on the planning committees of various conferences focused on cancer disparities and cancer prevention. She is also a peer reviewer for a number of professional journals.
Zeigler-Johnson earned her doctoral degree in epidemiology and a master’s of Public Health with a focus on epidemiology, both from the University of Pittsburgh. She completed her postdoctoral training in molecular epidemiology at the University of Pennsylvania.
She is an executive team member of the African Caribbean Cancer Consortium, a collaborative research group of more than 150 members from 17 institutions in the United States and 23 countries in the Caribbean and Africa, for which she leads the Environment and Genetics in African Ancestry Working Group. In addition, she is an active member of the American Association for Cancer Research and is a member of the American Society of Preventive Oncology. She also serves as a member of the Pennsylvania Cancer Coalition of the Pennsylvania Department of Health and recently completed a four-year term as co-chair of the Coalition’s Disparities Subcommittee. Collapse
Prostate cancer disparities and risk factors that influence prostate cancer occurrence, progression, and treatment outcomes.
The relationship between community history and prostate cancer disparities.
Increasing lung cancer screening access and adherence in vulnerable populations.
Neighborhood Characteristics and Prostate Cancer Disparities – One of my primary research interests involves using the characteristics of neighborhoods to determine disparities in prostate cancer. Although prostate cancer survival has improved over the years through advanced treatment options and methods of early detection, disparities still exist both socioeconomically and racially.
In our previous research, my team and I have used methods such as geospatial analysis to identify neighborhoods in Philadelphia with the highest prostate cancer burden. Through our study, Empowering Men about Prostate Cancer Together (EMPaCT), we were able to develop and test a targeted intervention that helped patients improve not only their knowledge of prostate cancer but their confidence in speaking with a physician about best options for screening.
Our work is continuing through the Pennsylvania Residential Opportunities to Improve Outcomes, Treatment, and Survival (PA-ROOTS) Study. This investigation combines geospatial analysis and mixed methods to study the role of patients’ residential histories, as well as the history of neighborhoods themselves, to determine how prostate cancer disparities are associated with structural racism as measured by historical redlining, lending bias, gentrification, and poverty. We seek to increase prostate cancer awareness in high-risk communities and encourage policies and practices that dismantle the structural barriers to health and healthcare that enable disparities to persist.
Outcomes in Prostate Cancer and Obesity – Although prostate cancer is common, it is a complex disease with strong ethnic disparities and few non-modifiable risk factors. Obesity, which is prevalent in African American populations, is a potentially modifiable risk factor and has been shown to increase the risk for advanced disease. Although obesity and advanced cancer individually have been linked to specific patient and neighborhood factors, these factors have not been studied as modifiers of obesity effects in prostate cancer patients.
Our research investigates disparities in the relationship between obesity and prostate cancer outcomes. By adjusting multilevel models for patient and neighborhood factors, we are able to determine whether significant modification by patient and neighborhood variables suggest new pathways for prostate cancer progression, identify groups of patients at highest risk for poor outcomes, and provide strategies for effective intervention to decrease disparities.
Inflammation of the Tumor Microenvironment – The tumor microenvironment, which consists of normal cells and other components that surround tumor cells, is of interest for researchers interested in uncovering how cancer develops and metastasizes.
One of the major characteristics of cancer that has been associated with disease severity is inflammation. When it occurs continuously, inflammation can cause immune cells such as T lymphocytes and macrophages in the tumor microenvironment to increase cell proliferation. The presence of these immune cells may be indicative of aggressive tumors that are likely to metastasize.
Being able to measure these changes in the tumor microenvironment under various conditions may help us identify tumor signatures that improve diagnostics of prostate cancer. The goal of this pathology-based research is to characterize differences in tumor-infiltrating lymphocytes and macrophages within the tumor microenvironment by obesity status and cancer severity.
The following ratings and reviews are based on verified feedback collected from independently administered
patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions.
Patient identities are withheld to ensure confidentiality and privacy.
Learn more about our Patient Experience Ratings.